• Home
  •  / Innovative Cellular Therapeutics

Innovative Cellular Therapeutics

  • Total Funding$28.3 M

OverviewSuggest Edit

Innovative Cellular Therapeutics (ICT, 斯丹赛生物技术) is a biotechnology company focused on the development of cellular immunotherapies for the treatment of cancer. Its lead candidate is ICTCAR014, a CD19-targeting CAR-T cell therapy that expresses a dominant-negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells.

TypePrivate
Founded2009
HQRockville, MD, USMap
Websiteictbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2022)17
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Innovative Cellular Therapeutics Office Locations

Innovative Cellular Therapeutics has an office in Rockville
Rockville, MD, US (HQ)
9601 Blackwell Rd Suite 210
Show all (2)

Innovative Cellular Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2009

Innovative Cellular Therapeutics total Funding

$28.3 m

Innovative Cellular Therapeutics latest funding size

$28.3 m

Time since last funding

4 years ago

Innovative Cellular Therapeutics investors

SBCVC, Volcanics Venture, ShenZhen GTJA Investment Group, Witruth Capital
Innovative Cellular Therapeutics's latest funding round in May 2018 was reported to be $28.3 m. In total, Innovative Cellular Therapeutics has raised $28.3 m
Show all financial metrics

Innovative Cellular Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

Innovative Cellular Therapeutics Online and Social Media Presence

Innovative Cellular Therapeutics's Trends

Embed Graph

Innovative Cellular Therapeutics News and Updates

May 26, 2022

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ROCKVILLE, Md., May 26, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the acceptance of an abstract for poster …
April 21, 2022

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

ROCKVILLE, Md., April 21, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented data at the 2022 …
April 19, 2022

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer

ROCKVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the U.S. Food and Drug Administrat…
April 06, 2022

Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer

ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Lucy Lu, M.D. a…
April 06, 2022

Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance

ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Robert Dallimor…
September 01, 2021

Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR® Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer

ROCKVILLE, Md., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a Maryland based clinical stage biotechnology company developing the CoupledCAR® platform of chimeric antigen receptor (CAR) T-cell therapies for solid tumors, today announced that the U.S. Food and Drug Adm…
Show more

 Innovative Cellular Therapeutics Frequently Asked Questions

  • When was Innovative Cellular Therapeutics founded?

    Innovative Cellular Therapeutics was founded in 2009.

  • How many employees does Innovative Cellular Therapeutics have?

    Innovative Cellular Therapeutics has 17 employees.

  • Who are Innovative Cellular Therapeutics competitors?

    Competitors of Innovative Cellular Therapeutics include PLIVA, 3sbio and Kyowa Kirin.

  • Where is Innovative Cellular Therapeutics headquarters?

    Innovative Cellular Therapeutics headquarters is located at 9601 Blackwell Rd Suite 210, Rockville.

  • Where are Innovative Cellular Therapeutics offices?

    Innovative Cellular Therapeutics has an office in Rockville.

  • How many offices does Innovative Cellular Therapeutics have?

    Innovative Cellular Therapeutics has 2 offices.